Navigation Links
A Unique Endoluminal Approach for the Treatment of Morbid Obesity Selected for Presentation at the 2009 American College of Surgeons Clinical Congress
Date:10/14/2009

CHICAGO, Oct. 14 /PRNewswire/ -- ValenTx, Inc. announces the presentation of the first clinical study of their endoluminal approach for the treatment of morbid obesity at the 2009 American College of Surgeons Clinical Congress. The ValenTx procedure is enabled by an implantable and removable sleeve that mimics the mechanisms of gastric bypass surgery without the risks associated with that procedure.

In a collaborative study led by physicians from the University of California San Diego Medical Center and the Imperial College of London, and conducted at the Hospital San Jose de Monterrey in Monterrey, Mexico, 12 patients underwent the implantation of the ValenTx bypass sleeve during a 12-week trial. Patients completing the study achieved an average excess weight loss of 39.5%.

"I'm very excited to present this work at the American College of Surgeons Clinical Congress," said Dr. Bryan J. Sandler, co-author on the study and presenter of the scientific paper. "This initial trial indicates that we can significantly reduce excess weight and positively impact the co-morbidities commonly seen in this patient population."

"We are very honored that the study of our device has been chosen for presentation at the ACS meeting," said James Wright, President of ValenTx. "We see the selection as an affirmation of our clinical focus: to develop a device with the proven therapy mechanisms of a highly effective bariatric procedure, but to enable this in a safer, less invasive manner."

In addition to an oral presentation of the study at the ACS Congress, a video presentation was accepted for the prestigious event. The clinical study will also be published in the Journal of the American College of Surgeons.

"This is very promising data," said Santiago Horgan, M.D., Director of UCSD's Center for the Treatment of Obesity and lead author on the study. "Furthermore, our experience with this device reveals the potential for a completely incision-less and reversible, outpatient procedure in the future."

The study concluded that the ValenTx device could be safely implanted and removed in all patients. In addition to achieving significant weight loss, diabetic patients in the study maintained normal fasting blood glucose levels, without anti hyperglycemic medications during the trial.

About ValenTx

ValenTx, Inc. is developing a less-invasive, implantable medical device to address morbid obesity. The Company's founding principle was to emulate the proven mechanisms of gastric bypass surgery, but with a less invasive, implantable, and removable device. ValenTx was initially funded by leading medical technology venture capital investors, Sapient Capital, EDF Ventures, Kaiser Permanente, Affinity Capital Partners, and T-Gap Ventures. A recent fundraising was led by SV Life Sciences and also included Covidien Ventures. ValenTx is based in Carpinteria, California.

SOURCE ValenTx, Inc.


'/>"/>
SOURCE ValenTx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
2. ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
3. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
4. Unique Hearing Aid Receives Patent Protection
5. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
6. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
7. CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals
8. Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data
9. Music & Medicine: Unique Collaboration Combines Performing Arts and Science
10. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
11. National Cancer Institute Research Identifies Unique Mechanism of Brostallicins Anti-Tumor Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... DDi , a Makro company, makes it to ... in eClinical Solutions. DDi has built its solution competency with a unique blend ... DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by providing ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... over 250 members of South Florida’s philanthropic community at its 10th anniversary Fashion ...
(Date:2/12/2016)... ... 2016 , ... Coco Libre, the maker of coconut water beverages with a ... Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut ... invitation-only gifting suite, held this year at the W Hollywood Hotel, has become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young ... area, celebrates the beginning of the latest charity campaign in their community enrichment ... art. Donations to this worthy cause are currently being accepted at: http://artexpressioninc.org/ ...
Breaking Medicine News(10 mins):